256 related articles for article (PubMed ID: 19298223)
41. Oral iron chelation and the treatment of iron overload in a pediatric hematology center.
Raphael JL; Bernhardt MB; Mahoney DH; Mueller BU
Pediatr Blood Cancer; 2009 May; 52(5):616-20. PubMed ID: 19148949
[TBL] [Abstract][Full Text] [Related]
42. Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1.
Wang H; Kubica N; Ellisen LW; Jefferson LS; Kimball SR
J Biol Chem; 2006 Dec; 281(51):39128-34. PubMed ID: 17074751
[TBL] [Abstract][Full Text] [Related]
43. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.
Kenerson H; Dundon TA; Yeung RS
Pediatr Res; 2005 Jan; 57(1):67-75. PubMed ID: 15557109
[TBL] [Abstract][Full Text] [Related]
44. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
Galanello R; Piga A; Forni GL; Bertrand Y; Foschini ML; Bordone E; Leoni G; Lavagetto A; Zappu A; Longo F; Maseruka H; Hewson N; Sechaud R; Belleli R; Alberti D
Haematologica; 2006 Oct; 91(10):1343-51. PubMed ID: 17018383
[TBL] [Abstract][Full Text] [Related]
45. Regulation of mTOR and cell growth in response to energy stress by REDD1.
Sofer A; Lei K; Johannessen CM; Ellisen LW
Mol Cell Biol; 2005 Jul; 25(14):5834-45. PubMed ID: 15988001
[TBL] [Abstract][Full Text] [Related]
46. Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.
Nick H; Allegrini PR; Fozard L; Junker U; Rojkjaer L; Salie R; Niederkofler V; O'Reilly T
Exp Biol Med (Maywood); 2009 May; 234(5):492-503. PubMed ID: 19234060
[TBL] [Abstract][Full Text] [Related]
47. Synthesis, characterization and in vitro anticancer evaluations of two novel derivatives of deferasirox iron chelator.
Salehi S; Saljooghi ASh; Shiri A
Eur J Pharmacol; 2016 Jun; 781():209-17. PubMed ID: 27090924
[TBL] [Abstract][Full Text] [Related]
48. Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells.
Kim JL; Lee DH; Na YJ; Kim BR; Jeong YA; Lee SI; Kang S; Joung SY; Lee SY; Oh SC; Min BW
Tumour Biol; 2016 Jul; 37(7):9709-19. PubMed ID: 26803514
[TBL] [Abstract][Full Text] [Related]
49. Effects of deferasirox on renal function and renal epithelial cell death.
Sánchez-González PD; López-Hernandez FJ; Morales AI; Macías-Nuñez JF; López-Novoa JM
Toxicol Lett; 2011 Jun; 203(2):154-61. PubMed ID: 21439361
[TBL] [Abstract][Full Text] [Related]
50. Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562.
Li N; Chen Q; Gu J; Li S; Zhao G; Wang W; Wang Z; Wang X
Oncotarget; 2017 May; 8(22):36517-36530. PubMed ID: 28388554
[TBL] [Abstract][Full Text] [Related]
51. Iron-induced cardiac damage: role of apoptosis and deferasirox intervention.
Wang Y; Wu M; Al-Rousan R; Liu H; Fannin J; Paturi S; Arvapalli RK; Katta A; Kakarla SK; Rice KM; Triest WE; Blough ER
J Pharmacol Exp Ther; 2011 Jan; 336(1):56-63. PubMed ID: 20947636
[TBL] [Abstract][Full Text] [Related]
52. Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.
Lescoat G; Chantrel-Groussard K; Pasdeloup N; Nick H; Brissot P; Gaboriau F
Cell Prolif; 2007 Oct; 40(5):755-67. PubMed ID: 17877614
[TBL] [Abstract][Full Text] [Related]
53. Enhanced brain delivery of deferasirox-lactoferrin conjugates for iron chelation therapy in neurodegenerative disorders: in vitro and in vivo studies.
Kamalinia G; Khodagholi F; Atyabi F; Amini M; Shaerzadeh F; Sharifzadeh M; Dinarvand R
Mol Pharm; 2013 Dec; 10(12):4418-31. PubMed ID: 24063264
[TBL] [Abstract][Full Text] [Related]
54. Clinical pharmacology of deferasirox.
Tanaka C
Clin Pharmacokinet; 2014 Aug; 53(8):679-94. PubMed ID: 24996374
[TBL] [Abstract][Full Text] [Related]
55. Deferasirox decreases age-associated iron accumulation in the aging F344XBN rat heart and liver.
Arvapalli RK; Paturi S; Laurino JP; Katta A; Kakarla SK; Gadde MK; Wu M; Rice KM; Walker EM; Wehner P; Blough ER
Cardiovasc Toxicol; 2010 Jun; 10(2):108-16. PubMed ID: 20229123
[TBL] [Abstract][Full Text] [Related]
56. Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.
Gaboriau F; Leray AM; Ropert M; Gouffier L; Cannie I; Troadec MB; Loréal O; Brissot P; Lescoat G
Biometals; 2010 Apr; 23(2):231-45. PubMed ID: 19997770
[TBL] [Abstract][Full Text] [Related]
57. RTP801 is a novel retinoic acid-responsive gene associated with myeloid differentiation.
Gery S; Park DJ; Vuong PT; Virk RK; Muller CI; Hofmann WK; Koeffler HP
Exp Hematol; 2007 Apr; 35(4):572-8. PubMed ID: 17379067
[TBL] [Abstract][Full Text] [Related]
58. Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells.
Calabrese C; Panuzzo C; Stanga S; Andreani G; Ravera S; Maglione A; Pironi L; Petiti J; Shahzad Ali MS; Scaravaglio P; Napoli F; Fava C; De Gobbi M; Frassoni F; Saglio G; Bracco E; Pergolizzi B; Cilloni D
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081324
[TBL] [Abstract][Full Text] [Related]
59. Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.
Chang YC; Lo WJ; Huang YT; Lin CL; Feng CC; Lin HT; Cheng HC; Yeh SP
Leuk Lymphoma; 2017 Sep; 58(9):1-12. PubMed ID: 28140713
[TBL] [Abstract][Full Text] [Related]
60. Hypoxia-induced regulation of mTOR signaling by miR-7 targeting REDD1.
Seong M; Lee J; Kang H
J Cell Biochem; 2019 Mar; 120(3):4523-4532. PubMed ID: 30302791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
